Company Overview of EQT Partners AB
EQT Partners AB is a private equity and venture capital firm specializing in expansion capital, mid venture, growth financing, buyouts, growth equity, middle market, industry consolidation, public-to private transactions, mezzanine financing, special situations including stressed and distressed situations; illiquid, and secondary investments. The firm also invests infrastructure with a focus on basic infrastructure, concession-based infrastructure, and infrastructure-related services; and debt of over-leveraged companies. The firm also seeks to invest in the industrials, healthcare, energy, environment, retail, business services, technology, media, and telecommunications sector. It prefers t...
Stockholm, 111 48
Founded in 1994
46 8 50 65 53 00
46 8 50 65 53 19
Key Executives for EQT Partners AB
Head of Finance and Chief Financial Controller
Compensation as of Fiscal Year 2014.
EQT Partners AB Key Developments
EQT Partners May Sell Or List Granngården
Aug 19 14
EQT Partners AB is rumoured to be planning to divest its portfolio company Granngården AB. According to Mergermarket sources, EQT is studying either an auction or a public listing for the company. Nordea is to manage the divestment, according to sources.
Five Companies Interested In Cheminova
Aug 15 14
Bain Capital, LLC, CVC Capital Partners Limited, EQT Partners AB, ADAMA Agricultural Solutions Ltd. and FMC Corp. (NYSE:FMC) are interested in acquiring Cheminova A/S, owned by Auriga Industries A/S (CPSE:AURI B), Berlingske Tidende reported.
Nobel Biocare Said To Draw Interests
Aug 11 14
Nobel Biocare Holding AG (SWX:NOBN) ) that’s exploring a sale, has attracted interest from potential buyers including EQT Partners AB and Danaher Corp. (NYSE:DHR), said people with knowledge of the matter. Nobel Biocare was initially approached by EQT with an offer of about CHF 17 a share, which would have valued the company at about CHF 2.1 billion said the people, who asked not to be identified because talks are private. The offer prompted Nobel Biocare and its adviser Goldman Sachs Group Inc. (GS) to invite other bids as it seeks a higher price, the people said. Other companies such as DENTSPLY International Inc. (NasdaqGS:XRAY) and buyout firms are also expected to look at Nobel Biocare, the people said. Potential buyers include Straumann Holding AG (SWX:STMN), Sirona Dental Systems Inc., Johnson & Johnson (NYSE:JNJ), Medtronic, Inc. (NYSE:MDT), Zimmer Holdings, Inc. (NYSE:ZMH), Henry Schein, Inc. (NasdaqGS:HSIC), and 3M Company (NYSE:MMM), according to a note on July 30 from Lisa Bedell Clive, a London-based analyst at Sanford C. Bernstein & Co. Nobel Biocare could sell for as much as CHF 18 a share, she said in the note.
Similar Private Companies By Industry
Recent Private Companies Transactions